1. A Multicenter Application of the 2018 Banff Classification for BK Polyomavirus-associated Nephropathy in Renal Transplantation
- Author
-
Yassine Bouatou, Frederike J. Bemelman, Laura A. Michielsen, Joris J. T. H. Roelofs, Tri Q. Nguyen, Jesper Kers, Roel Goldschmeding, Sandrine Florquin, Graduate School, Pathology, ACS - Diabetes & metabolism, ACS - Pulmonary hypertension & thrombosis, AII - Inflammatory diseases, Nephrology, APH - Digital Health, APH - Global Health, and APH - Aging & Later Life
- Subjects
Adult ,Graft Rejection ,Male ,medicine.medical_specialty ,Biopsy ,Renal function ,030230 surgery ,Kidney ,medicine.disease_cause ,Nephropathy ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Journal Article ,medicine ,Humans ,Kidney transplantation ,Retrospective Studies ,Polyomavirus Infections ,Transplantation ,medicine.diagnostic_test ,business.industry ,Graft Survival ,Retrospective cohort study ,Middle Aged ,medicine.disease ,Kidney Transplantation ,Transplant Recipients ,BK virus ,Tumor Virus Infections ,BK Virus ,Cohort ,Nephritis, Interstitial ,Female ,030211 gastroenterology & hepatology ,business ,Follow-Up Studies ,Glomerular Filtration Rate - Abstract
BACKGROUND: With current immunosuppressive regimens, BK polyomavirus-associated nephropathy (BKPyVAN) is still a matter of concern. Stratification of patients at risk for allograft loss is of uttermost importance to guide treatment choice and assess prognosis. In 2018, the Banff working group proposed a classification scheme for the prognosis of BKPyVAN, but external application on independent cohorts is yet to be performed. We investigated how the 2018 Banff classification would perform in a multicenter cohort comprising 50 cases of biopsy-proven BKPyVAN compared to previously published classification systems. METHODS: We analyzed consecutive BKPyVAN cases from two Dutch university hospitals between 2002 and 2013, retrieved clinical data, and scored all biopsies according to the Banff 2018 classification, and as a comparison, 4 previously proposed BKPyVAN classification systems. We used estimated glomerular filtration rate trajectories and death-censored graft survival as primary endpoints. RESULTS: The 2018 Banff classification did not associate with estimated glomerular filtration rate decline or graft failure and performed only slightly better than the 4 previously proposed classifiers. Anti-human leukocyte antigen donor-specific antibodies (DSAs), especially in combination with ongoing biopsy-proven BKPyVAN on follow-up, did correlate with graft function and survival. Patients who were DSA+/BKPyVAN+ on follow-up had more inflammation at the baseline biopsy, which by itself was not associated with graft outcomes. CONCLUSIONS: Neither the 2018 Banff BKPyVAN classification nor previously published stratification systems could be applied to our multicenter patient cohort. Our data suggest that there might be a prognostic value for follow-up biopsies and DSA measurements to improve risk stratification after BKPyVAN, although prospective multicenter efforts with protocol measurements are needed to confirm this.
- Published
- 2019
- Full Text
- View/download PDF